Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Trial Profile

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top